New cellular therapy for Hodgkin Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and effectiveness of ATLCAR.CD30.CCR4 cells in patients with Hodgkin Lymphoma that is relapsed or refractory. It is a single-center, open-label study that aims to determine the tolerability of this novel cellular therapy and establish a recommended dose for further investigation. The trial employs a 3+3 design to identify the optimal dose and includes a phase II component to assess progression-free survival in participants. Patients may receive standard-of-care therapies during the study to stabilize their condition.

Why it matters

Who can join: the full rules

During the period of cell procurement and lymphodepletion, subjects will be eligible to receive standard-of-care therapy e.g., chemotherapy or radiation therapy to stabilize their disease if the treating physician feels it is in the subject's best interests. Eligibility must be maintained up until the subject is procured, receives lymphodepletion, or receives treatment for the subject to be considered eligible to proceed with the specific phase of the study.

Inclusion Criteria:

Unless otherwise noted, subjects must meet all of the following criteria to participate in all phases of the study. As these criteria are unchanging they will be evaluated at the time of initial enrollment and not continuously throughout the study.

1. Written informed consent and HIPAA authorization for release of personal health information explained to, understood by, and signed by the subject or legally authorized representative.
2. Age ≥ 18 years at the time of consent.
3. Karnofsky score of \> 60%
4. The subject must have a diagnosis of Classical Hodgkin Lymphoma according to World Health Organization criteria.

Exclusion Criteria:

1. Subjects had major surgery within 28 days.
2. Subject received investigational agents or tumor vaccines within 3 weeks.
3. Subject received chemotherapy or radiation therapy within the previous 3 weeks.

Where it's running

• Lineberger Comprehensive Cancer Center
  Chapel Hill, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Natalie Grover, MD — UNC Lineberger Comprehensive Cancer Center
• Study coordinator: Catherine Cheng
• Email: UNCImmunotherapy@med.unc.edu
• Phone: +1 919-445-4208

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Daratumumab for refractory aplastic anemia in adults

  This trial tests whether daratumumab can be safely given and help people with refractory aplastic anemia see a benefit.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07287228

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• JLM019 Injection in Adults with Advanced Cancers

  This study tests JLM019 Injection in adults with advanced solid tumors or relapsed/refractory lymphomas to see if it’s safe and tolerable.

  Recruiting Phase 1 Jecho Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07623850

• How facial type relates to relapse after orthodontic treatment during retention

  This study tests whether people with different facial types have different patterns of tooth movement relapse after orthodontic treatment during the retention phase.

  Recruiting Postgraduate Institute of Dental Sciences Rohtak · Rohtak, Haryana · NCT07622277

• Can a multi-omics and AI model predict ABPA relapse within 1 year in adults?

  This study tests a machine learning model that uses multi-omics and clinical data to predict the 1-year relapse risk for adults with ABPA who are in a stable state.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07611838

• Serplulimab plus second-line chemo/targeted therapy for early-relapse colorectal cancer after adjuvant therapy

  This trial tests whether adding serplulimab to standard second-line chemotherapy plus targeted therapy helps people whose colorectal cancer came back early after adjuvant treatment.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07604909

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.